TY - JOUR
T1 - Report of the 21st Nationwide Follow-up Survey of Primary Liver Cancer in Japan (2010–2011)
AU - Kudo, Masatoshi
AU - Izumi, Namiki
AU - Kokudo, Norihiro
AU - Sakamoto, Michiie
AU - Shiina, Shuichiro
AU - Takayama, Tadatoshi
AU - Tateishi, Ryosuke
AU - Nakashima, Osamu
AU - Murakami, Takamichi
AU - Matsuyama, Yutaka
AU - Takahashi, Arata
AU - Miyata, Hiroaki
AU - Kubo, Shoji
N1 - Publisher Copyright:
© 2021 The Authors. Hepatology Research published by John Wiley & Sons Australia, Ltd on behalf of Japan Society of Hepatology
PY - 2021/4
Y1 - 2021/4
N2 - In the 21st Nationwide Follow-up Survey of Primary Liver Cancer in Japan, data from 22,134 new patients and 41,956 previously followed patients were compiled from 546 institutions over a 2-year period from 1 January 2010 to 31 December 2011. Basic statistics compiled for patients newly registered in the 21st survey were cause of death, medical history, clinical diagnosis, imaging diagnosis, treatment-related factors, pathological diagnosis, recurrence status, and autopsy findings. Compared with the previous 20th survey, the population of patients with hepatocellular carcinoma (HCC) was older at the time of clinical diagnosis, had more female patients, had more patients with non-B non-C HCC, had smaller tumor diameter, and was more frequently treated with hepatectomy and with radiofrequency ablation. Cumulative survival rates were calculated for HCC, intrahepatic cholangiocarcinoma, and combined hepatocellular cholangiocarcinoma (combined HCC and intrahepatic cholangiocarcinoma) by treatment type and background characteristics for patients newly registered between 1998 and 2011 whose final outcome was survival or death (excluding unknown). Cumulative survival rates for HCC were calculated by dividing patients by combinations of background factors (number of tumors, tumor diameter, and Child–Pugh grade) and by treatment type (hepatectomy, local ablation therapy, transcatheter arterial chemoembolization, and hepatic arterial infusion chemotherapy). The same values were also calculated according to registration date by dividing patients newly registered between 1978 and 2011 into four time-period groups. The data obtained from this nationwide follow-up survey are expected to contribute to advancing clinical research and treatment of primary liver cancer.
AB - In the 21st Nationwide Follow-up Survey of Primary Liver Cancer in Japan, data from 22,134 new patients and 41,956 previously followed patients were compiled from 546 institutions over a 2-year period from 1 January 2010 to 31 December 2011. Basic statistics compiled for patients newly registered in the 21st survey were cause of death, medical history, clinical diagnosis, imaging diagnosis, treatment-related factors, pathological diagnosis, recurrence status, and autopsy findings. Compared with the previous 20th survey, the population of patients with hepatocellular carcinoma (HCC) was older at the time of clinical diagnosis, had more female patients, had more patients with non-B non-C HCC, had smaller tumor diameter, and was more frequently treated with hepatectomy and with radiofrequency ablation. Cumulative survival rates were calculated for HCC, intrahepatic cholangiocarcinoma, and combined hepatocellular cholangiocarcinoma (combined HCC and intrahepatic cholangiocarcinoma) by treatment type and background characteristics for patients newly registered between 1998 and 2011 whose final outcome was survival or death (excluding unknown). Cumulative survival rates for HCC were calculated by dividing patients by combinations of background factors (number of tumors, tumor diameter, and Child–Pugh grade) and by treatment type (hepatectomy, local ablation therapy, transcatheter arterial chemoembolization, and hepatic arterial infusion chemotherapy). The same values were also calculated according to registration date by dividing patients newly registered between 1978 and 2011 into four time-period groups. The data obtained from this nationwide follow-up survey are expected to contribute to advancing clinical research and treatment of primary liver cancer.
KW - Liver Cancer Study Group of Japan
KW - combined hepatocellular cholangiocarcinoma
KW - cumulative survival rate
KW - hepatocellular carcinoma
KW - intrahepatic cholangiocarcinoma
KW - nationwide follow-up survey
UR - http://www.scopus.com/inward/record.url?scp=85101918975&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101918975&partnerID=8YFLogxK
U2 - 10.1111/hepr.13612
DO - 10.1111/hepr.13612
M3 - Article
AN - SCOPUS:85101918975
SN - 1386-6346
VL - 51
SP - 355
EP - 405
JO - Hepatology Research
JF - Hepatology Research
IS - 4
ER -